Regeneron’s Q2 explodes with record-breaking growth—revenue up 17%, EPS up 11%—as Dupixent, EYLEA HD, and Libtayo smash quarterly sales highs. Dupixent alone rakes in $6B globally, up 38%, with expansion into new markets and age groups on the horizon. EYLEA HD now outsells its predecessor, fueled by 24% higher physician demand and a pending prefilled syringe approval. Libtayo surges 29% with growing use in skin and lung cancers. With 50 clinical programs advancing and key FDA decisions looming—including a November submission for cemdisiran in myasthenia gravis—Regeneron’s pipeline is primed for explosive 2024.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
